Supplementary Fig. 11: EBV-specific T cells can be re-directed to target tumor cells using APEC and CMV-CTL activation using different proteases to cleave APECs. | Nature Biotechnology

Supplementary Fig. 11: EBV-specific T cells can be re-directed to target tumor cells using APEC and CMV-CTL activation using different proteases to cleave APECs.

From: Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy

Supplementary Fig. 11

(a) Tumor cells treated with APEC conjugated with EBV-derived epitopes are recognised by EBV-specific T cells (n=3 independent samples). Data represented as mean and error bars represent standard error of the mean. Significance was determined by unpaired two-tailed t-test. (b) Multiple tumor types can be recognized by peptide-specific T cells after treatment with cAPEC containing ADAM28, MMP2, MMP9 or MMP14 cleavable peptides (n=3 independent samples). Data represented as mean and error bars represent standard error of the mean.

Back to article page